Cancer-style 'immune reset' puts severe lupus into remission in UK trial

A therapy first developed to fight blood cancer has shown early promise in severe lupus, with researchers reporting that a single infusion drove the disease into remission in most patients in an NHS trial. The findings, from a study led by University College London and University College London Hospitals, raise the prospect of a one-off treatment that resets a malfunctioning immune system rather than suppressing it for life.

In the lower-dose group of the Phase I CARLYSLE study, five of six patients with severe, treatment-resistant systemic lupus erythematosus achieved remission according to standard lupus criteria, with responses emerging within a few months of treatment. Researchers described the early safety data as favourable, an important consideration for a powerful therapy being used in a non-cancer setting for the first time in the UK.

This article is general information about an experimental treatment in early-stage trials and is not medical advice. Lupus patients should not change any treatment without speaking to their own specialist team.

How the treatment works

CAR T-cell therapy involves collecting a patient's own immune cells, re-engineering them in a laboratory to recognise a specific target, and then infusing them back into the body. The therapy used in the trial, obecabtagene autoleucel, was designed to find and deplete CD19-positive B cells, the immune cells that produce the rogue antibodies central to lupus. By clearing out these cells, the approach aims to wipe the slate clean so the immune system can rebuild without the faulty programming that causes it to attack healthy tissue.

That is why scientists describe the strategy as an immune reset rather than ongoing suppression. Conventional lupus treatment relies on drugs that dampen the immune system, often for years, with side effects and incomplete control. A therapy that needs to be given only once, if its benefits prove durable, would represent a fundamentally different model of care.

“These findings provide early evidence that CAR T-cell therapy may be able to reset the immune system and drive meaningful clinical improvements after a single treatment.”

— Dr Claire Roddie, UCL Cancer Institute

What the results showed

Across the trial, several adult patients with severe disease were treated, spanning a wide age range. The headline finding was the remission rate in the lower-dose cohort, but researchers were equally encouraged by the safety profile. They reported no cases of the serious neurological side effect known as immune effector cell-associated neurotoxicity syndrome, and no moderate-to-severe cytokine release syndrome, two of the complications most feared with CAR T-cell therapy.

• Study: the Phase I CARLYSLE trial led by UCL and UCLH
• Therapy: obecabtagene autoleucel, engineered to deplete CD19-positive B cells
• Outcome: five of six lower-dose patients in remission within months
• Safety: no severe neurotoxicity and no moderate-to-severe cytokine release syndrome reported
• One dose-limiting liver injury occurred but fully resolved

One patient experienced a dose-limiting liver injury, which fully resolved, and other side effects were described as manageable and in line with expectations. While these are early numbers from a small, carefully selected group, they add to a growing international body of evidence that B-cell-targeting cell therapies could transform care for some autoimmune conditions.

Who could benefit

Lupus is a chronic autoimmune disease in which the immune system attacks the body's own tissues, causing inflammation that can affect the skin, joints, kidneys and other organs. It disproportionately affects women and people of certain ethnic backgrounds, and severe forms can be debilitating and difficult to control with existing drugs. The patients in the trial were those whose disease had not responded adequately to standard treatment, the group with the greatest unmet need.

For these patients, the promise of a single treatment that could lift the burden of daily medication and persistent symptoms is significant. Clinicians caution, however, that CAR T-cell therapy is intensive, requires specialist centres, and is not a candidate for routine first-line use; the early data are about proving the concept in the hardest cases.

“For people whose lupus has resisted everything we can throw at it, the idea of resetting rather than endlessly suppressing the immune system is genuinely exciting, but we must let the longer-term data mature.”

— a researcher in autoimmune medicine

Background

The therapy was developed by a UCL spinout company, building on years of work in cancer immunotherapy before being trialled in autoimmune disease. The UK delivered its first CAR T-cell treatment for lupus in late 2024, and the latest results represent the maturing data from that programme. The work sits within a wider global wave of research exploring whether cell therapies pioneered in oncology can be repurposed for conditions in which the immune system turns on the body.

What happens next

Researchers are continuing to monitor the durability of responses, the optimal dose, and long-term safety, and a Phase II trial is recruiting at multiple UK sites for patients with severe lupus affecting the kidneys. Larger and longer studies will be needed before the therapy could be considered for wider NHS use. For now, the message from the team is one of cautious optimism: early evidence that a single, cancer-derived treatment may be able to switch off one of medicine's most stubborn autoimmune diseases.